GLP-1
As the second day of the 42nd J.P. Morgan Healthcare Conference dawned in San Francisco, experts from Boston Consulting Group, Merck, CVC and more provided their outlook on the year ahead.
BioSpace continues to bring you the latest news and industry developments from the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. Stay tuned!
After a topsy-turvy 2023, thousands of industry stakeholders will attend next week’s J.P. Morgan Healthcare Conference in San Francisco to answer a fundamental question: What will this year look like?
The therapeutic targets of many of our top startups are also reflected in recent big biopharma acquisitions and partnerships.
While initial public offering activity was light in 2023, the new year has recorded the first IPO plan—from California-based CG Oncology.
Eli Lilly on Thursday announced the rollout of a new digital healthcare platform to streamline consumer access to its weight-loss drug Zepbound and other medications.
The regulator is launching an investigation of Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound and other GLP-1 receptor agonists following patient reports of suicidal ideation, alopecia and aspiration.
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
While GLP-1 drugs have exploded in popularity, they don’t work for everyone, and experts say phenotyping based on a greater understanding of the disease is the future of obesity treatment.
In a collaboration agreement announced Wednesday, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for nonalcoholic or metabolic dysfunction-associated steatohepatitis.
PRESS RELEASES